GeneDx (WGS) Q3 2026 earnings review
GeneDx collects higher payments per test, but cuts growth targets
GeneDx, a genetics lab that sequences DNA to diagnose rare diseases, is getting paid more per test while its test volume slows down. Third-quarter sales grew 5% from a year ago to $123 million as average payment per core exome and genome test rose 5% from last quarter, lifting profit excluding one-offs to $9 million. However, completed core test volume missed the company's target, forcing chief executive Katherine Stueland to cut full-year growth floors for core volume and core revenue for a second time this year.
| Exome and genome revenue | $110.4M +12% from a year ago |
|---|---|
| Average revenue per exome/genome test | ~$3,430 +5% from last quarter (plan: ~$3,300) |
| Net profit, excluding one-offs | $8.6M plan: ~$2.0M (GAAP net loss: -$12.3M) |
| Full-year exome/genome revenue outlook | Cut to ≥17% prior: ≥20% (total revenue held at $475–490M) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because higher reimbursement per test and lower full-year volume targets cancelled each other out. Average revenue per core test climbed to about $3,430 and the fourth-quarter plan points to $3,507 by our math, easing the main worry that insurance payments were stuck. The bad news: cutting the full-year core revenue growth floor to 17% confirms that the earlier 20% target was out of reach, and free cash flow burn reached $16 million in the quarter.
The question now is whether rising payment per test comes from insurers paying new whole genome claims or from one-time accounting adjustments to older bills. If new insurance policies are paying out, fourth-quarter collections will turn cash flow positive; if accounting adjustments drove the gain, unpaid bills will keep climbing. The quarterly filing's revenue footnote and fourth-quarter cash flow will settle it.
🐂 Bull Case
Average Payment Per Test Turned Upward
GeneDx sequences a patient's exome (the protein-coding part of DNA) or whole genome to diagnose rare diseases. Average revenue per test fell earlier this year because orders shifted toward whole genome tests, which insurers paid less often. This quarter, average revenue per exome and genome test rose 5.5% from last quarter to $3,436 by our math, beating the $3,300 plan.
The genetics lab reported "Q3 ARR up 5% sequentially to ~$3,430" and noted "No material changes to underlying average contracted rates this quarter" in its presentation. Because contract prices stayed the same, the higher average payment came from collecting on more claims and steering doctors toward tests with better insurance coverage. By our math, the fourth-quarter outlook points to $3,507 per test.
What to watch: the exact outpatient collection rate and prior-period billing adjustments in the quarterly filing. A rise above the 32% collection rate from the first half, without a large one-time billing true-up, would prove that newly added insurance policies are paying out.
Gross Margin and Profit Targets Moved Up
Better payment per test and earlier staff cuts lifted margins past the company's plan. Gross margin excluding one-offs (revenue left after the cost of running the lab) rose to 71.6% from 70.4% last quarter, beating the 70% target. Selling and administrative overhead excluding one-offs fell by 3.4 percentage points of revenue from last quarter to 52.0%, though it remains 7.6 points higher than a year ago.
Net profit excluding one-offs reached $8.6 million against a $2 million plan, and management raised the full-year profit target to about $12 million. However, new accounting adjustments flattered that result. The rare-disease specialist still lost $12.3 million under standard accounting, and its adjusted profit now strips out $1.8 million of net interest expense, $1.2 million of vacant lease costs, and "third party advisor fees related to our Revenue Cycle Transformation".
What to watch: operating profit under standard accounting in the fourth quarter. Shrinking the gap between standard losses and adjusted profit will show whether cost discipline is outrunning consulting and interest bills.
Payer Coverage and Ordering Tools Keep Expanding
The company is trying to win orders from general pediatricians while getting more state Medicaid programmes to pay for whole genome sequencing. This quarter, Arkansas and Utah Medicaid added coverage for whole genome tests, bringing the total to 25 states. Management also hired Nicole Maassen as Chief Patient Access Officer for "translating positive coverage policies into timely access for children who need testing".
On the product side, the diagnostics provider rolled out "simplified test reports, easy ordering, and report guides" for doctors and launched "long-read whole genome sequencing" to defend its share in advanced testing. It also opened an online service where families of children with developmental delays or epilepsy can connect with doctors to order exome tests "without requiring traditional in-person visits".
What to watch: test volume from the "Dedicated team of ~50 sales reps expected to drive impact by the end of 2026 and into 2027". Because selling overhead is up 7.6 percentage points of revenue from a year ago, those reps must start bringing in orders in the fourth quarter to justify their cost.
🐻 Bear Case
Core Growth Targets Cut for a Second Time
"Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth," chief executive Katherine Stueland said. Yet for the second time this year, the testing company cut its full-year growth targets for exome and genome tests after third-quarter completed test volume missed its own plan.
- Q3 exome and genome test volume: 32,134 tests (up 25% from a year ago), missing the 33,200 target
- Full-year exome and genome volume growth outlook: cut to at least 28%, down from 30% last quarter and 33–35% at the start of the year
- Full-year exome and genome revenue growth outlook: cut to at least 17%, down from 20% last quarter and 33–35% at the start of the year
- Full-year total revenue implied by Q4 outlook: $474.8 million by our math, just below the reiterated $475–490 million range
The company noted that accessions (incoming test samples) grew 28% from a year ago, three points faster than completed test results. Even so, the fourth-quarter target of $121 million in exome and genome sales fell $9.5 million short of what the old 20% full-year floor required by our math, proving that third-quarter payment gains could not make up for slower test counts.
What to watch: whether fourth-quarter exome and genome volume clears 34,500 tests. Another shortfall would show that stricter insurance checks prior to testing are slowing down doctors' orders.
Cash Burn Continues While Debt Triples
Higher adjusted profit has not yet turned into cash in the bank. By our math from the nine-month cash flow statement, the Maryland-based company used $10.6 million of cash in its operations during the third quarter and spent $5.2 million on lab equipment and software, burning $15.8 million of free cash flow. Over the first nine months of 2026, free cash flow burn reached $93.8 million.
Cash stayed tied up in unpaid bills: accounts receivable (money owed by insurers and patients) climbed to $92.1 million, up 23.9% since December while third-quarter revenue grew 5.4% from a year ago. To keep $171.1 million of total cash on hand after the August Blackstone loan expansion, the business tripled its long-term debt from $48.2 million at year-end to $146.2 million, cutting net cash to $24.9 million by our math.
What to watch: fourth-quarter operating cash flow, which finance chief Kevin Feeley previously committed would turn positive. Continuing to burn cash while carrying $146.2 million of debt would pressure the balance sheet in 2027.
Risks this quarter didn't answer
Four standing concerns could not be read from the earnings release and slide deck because the company discloses them on the conference call or in its quarterly filing.
- Outpatient genome collection rate and genome share of test volume: slide 19 names both as key metrics without printing clear third-quarter percentages; the call transcript will show whether collections moved off 32% and whether genome mix stayed near 30%.
- Prior-period billing estimate changes: in the second quarter, $7.3 million of revenue came from upward adjustments to older quarters' bills; the quarterly filing's revenue footnote will show how much of the third-quarter payment jump came from similar true-ups.
- Lab supply costs: whole genome tests cost nearly twice as much to run as exome tests, with cost relief previously pushed to 2027; the call will show if supplier pricing changed.
- Shareholder lawsuits over Fabric Genomics: two class-action suits filed in June and July over the impaired software acquisition were not mentioned in the release; the quarterly filing's legal footnote will carry any update.
💲 Other KPIs
Sales of older, narrower gene panel tests fell 33.6% from a year ago and 16.4% from last quarter as doctors switched to full exome and genome tests. Panel test volume dropped 23.1% from a year ago to 26,524 tests, holding total company revenue growth to 5.4% despite 11.6% growth in exome and genome sales.
Uncollected customer and insurer bills rose 51.2% from a year ago and 23.9% from the end of 2025, outpacing third-quarter revenue growth of 5.4%. Because GeneDx books revenue based on expected collections before insurers actually pay, rising receivables drained $18.0 million of operating cash over the first nine months.
The diluted share count used for profit excluding one-offs rose 2.0% from a year ago and 2.0% from last quarter. The increase reflects employee stock compensation and the August private sale of shares to Blackstone alongside the expanded term loan.
🔮 Guidance
Unchanged. The full-year target still calls for 12.9% growth at the middle of the range, after management cut it by $65 million in the first quarter. However, by our math, nine-month sales of $339.8 million plus the new $135 million fourth-quarter target add up to $474.8 million, sitting right at the bottom edge of the annual range.
Cut. Management lowered the full-year volume growth floor by 2 percentage points after third-quarter volume missed its target. It is the second cut this year: the floor started at 33–35%, dropped to 30% in the first quarter, held in the second, and now sits at 28%. By our math, the fourth-quarter target of 34,500 tests leaves the year at 28.4% growth.
Cut. The genomics group lowered its core revenue growth floor by 3 percentage points. That marks a second reduction this year, down from 33–35% originally and 20% in the first and second quarters. By our math, adding the $121 million fourth-quarter outlook to nine-month results gives $422.3 million, or 17.2% growth for the year.
Raised. The full-year gross margin target moved up 1 percentage point to 71% after the third quarter reached 71.6%, recovering the 1-point trim made in the first quarter.
Raised. After previously promising only a positive full-year figure, the lab set a specific target of about $12 million. Because net profit excluding one-offs totaled $0.8 million across the first three quarters ($8.2 million loss in Q1, $0.4 million profit in Q2, and $8.6 million in Q3), the annual plan matches the $12 million fourth-quarter target.
New. The fourth-quarter plan calls for total sales to rise 11.6% from a year ago and 9.7% from the third quarter, up from 5.4% annual growth this quarter.
New. Fourth-quarter test volume is set to grow 24.3% from a year ago and 7.4% from the third quarter, slightly below the 25.0% annual growth recorded in the third quarter.
New. The plan calls for core test sales to grow 16.3% from a year ago and 9.6% from the third quarter. Paired with the 34,500 test target, that implies an average payment of $3,507 per test by our math, up 2.1% from the third quarter.
New. Management expects fourth-quarter gross margin excluding one-offs to stay at or above 71%, roughly matching the 71.6% delivered in the third quarter.
New. Profit excluding one-offs is planned to rise from $8.6 million in the third quarter to about $12 million in the fourth, driven by the $12 million sequential step-up in revenue.
❓ Key Questions
What was the exact outpatient collection rate in Q3?
Slide 19 lists the outpatient genome collection rate as a key metric without printing a clear third-quarter percentage. Investors need to know if collections actually rose above the 32% rate from the first half.
How much of Q3 revenue came from prior-period billing adjustments?
In the second quarter, $7.3 million of revenue came from upward adjustments to older quarters' bills. Without the third-quarter figure from the filing, it is unclear how much of the jump to $3,436 per test came from current tests.
Why did completed test volume miss when orders grew 28%?
Incoming test samples grew 28% from a year ago, but completed exome and genome test results grew 25% and missed the 33,200 target. Management did not explain whether lab turnaround times or missing insurance paperwork held tests back.
Will operating cash flow still turn positive in Q4?
The company burned $10.6 million of operating cash in the third quarter as unpaid customer bills rose to $92.1 million. Management did not repeat its earlier promise to generate positive cash flow in the fourth quarter.